Novartis

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

Novartis today broke ground on a new, state-of-the-art global Biomedical Research center in San Diego, California, designed to provide world-class scientific infrastructure and drug-discovery ...
Novartis

Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025

The Novartis Board of Directors proposes a dividend payment of CHF 3.70 per share for 2025, up 5.7% from CHF 3.50 per share in the prior year, representing the 29th consecutive dividend increase since ...
Novartis

Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS

Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breaker Scemblix data across clinical and real-world settings ...
Novartis

Novartis announces plans to build flagship manufacturing hub in North Carolina

Expansion represents significant investment in North Carolina and is expected to create 700 new jobs in the state by end of 2030 Enables manufacturing of medicines across company’s main therapeutic ...
Novartis

New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline

. *Novartis has obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals, a leader in RNAi therapeutics.
Novartis

Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials

Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren’s disease, the second most prevalent rheumatic autoimmune disease 2, at a late-breaker presentation during the American ...
Novartis

Novartis completes acquisition of Tourmaline Bio

. Novartis is providing the information in this press release as of this date, and Novartis does not undertake any obligation to update any forward-looking statements contained in this press release ...
Novartis

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

Basel, October 26, 2025 – Novartis today announced that it has entered into an agreement to acquire Avidity Biosciences, Inc. (Nasdaq: RNA), a San Diego-based, biopharmaceutical company focused on a ...
Novartis

Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)

Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521 Trial showed reduction in annual cumulative steroid dose vs placebo ...
Novartis

PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer

Pluvicto TM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic ...
Novartis

Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)

In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years 1 ...
Novartis

Novartis to launch Direct-to-Patient platform for Cosentyx® (secukinumab) in the US

Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025 DTP offering to expand to other appropriate products; ...